ACW XanaMIA trial fully enrolled with 246th participant
Filed with ASX · · 29 pages · English
Sydney, 18 December 2025. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that due to the recent accelerated screening and enrolment in the XanaMIA phase 2b/3 Alzheimer’s disease (AD) trial, the Company has randomized and commenced treatment of all participants. This means that topline, final results will be available in November next year. Key points: • XanaMIA is a ran
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- ACW positive XanaMIA Data Monitoring Committee meeting
- ACW September 2025 quarterly activity report & Appendix 4C
- ACW confirms eligibility for further $1.9m RDTI
- ACW achieves early screening closure for XanaMIA trial
- ACW receives initial $5.5m R&D tax incentive rebate
Later from Actinogen Medical
- Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
- Actinogen secures $4.3m of non-dilutive R&D tax funding
- Trading Halt
- ACW positive XanaMIA Interim Analysis outcome
- Continuation of Trading Halt
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical